An issue of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) debt rose 1.1% as a percentage of its face value during trading on Thursday. The debt issue has a 3.15% coupon and will mature on October 1, 2026. The debt is now trading at $84.25 and was trading at $82.88 last week. Price moves in a company’s debt in credit markets sometimes predict parallel moves in its stock price.

TEVA has been the topic of several research analyst reports. Citigroup set a $25.00 price objective on Teva Pharmaceutical Industries and gave the company a “buy” rating in a research note on Thursday, May 31st. Barclays set a $23.00 price objective on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Thursday, August 2nd. Mizuho reiterated a “buy” rating and issued a $27.00 price objective on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 2nd. Cantor Fitzgerald set a $25.00 target price on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Friday, July 13th. Finally, Morgan Stanley increased their target price on Teva Pharmaceutical Industries from $19.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Friday, August 3rd. Eight equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $20.70.

Shares of TEVA stock traded up $0.01 on Thursday, reaching $22.21. The company’s stock had a trading volume of 10,359,500 shares, compared to its average volume of 12,831,347. The company has a debt-to-equity ratio of 1.86, a quick ratio of 0.69 and a current ratio of 1.03. Teva Pharmaceutical Industries Ltd has a 12-month low of $10.85 and a 12-month high of $25.96. The company has a market capitalization of $22.25 billion, a PE ratio of 5.72, a price-to-earnings-growth ratio of 2.73 and a beta of 0.69.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Thursday, August 2nd. The company reported $0.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.64 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 19.92% and a negative net margin of 47.98%. The company had revenue of $4.70 billion for the quarter, compared to the consensus estimate of $4.75 billion. During the same quarter last year, the business posted $1.02 earnings per share. The firm’s revenue was down 17.8% compared to the same quarter last year. sell-side analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.67 EPS for the current fiscal year.

In related news, EVP Iris Beck Codner sold 4,165 shares of the stock in a transaction on Thursday, August 9th. The stock was sold at an average price of $22.70, for a total value of $94,545.50. Following the sale, the executive vice president now owns 8,290 shares in the company, valued at $188,183. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sven Dethlefs acquired 2,000 shares of the stock in a transaction that occurred on Friday, August 3rd. The stock was acquired at an average price of $21.92 per share, for a total transaction of $43,840.00. Following the transaction, the executive vice president now directly owns 6,445 shares of the company’s stock, valued at approximately $141,274.40. The disclosure for this purchase can be found here. Company insiders own 0.43% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MAI Capital Management bought a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at about $204,000. Bank of Nova Scotia bought a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at about $299,000. Miller Value Partners LLC grew its stake in shares of Teva Pharmaceutical Industries by 17.9% during the second quarter. Miller Value Partners LLC now owns 2,588,612 shares of the company’s stock valued at $62,955,000 after buying an additional 393,640 shares during the last quarter. HPM Partners LLC grew its stake in shares of Teva Pharmaceutical Industries by 25.4% during the second quarter. HPM Partners LLC now owns 14,657 shares of the company’s stock valued at $356,000 after buying an additional 2,971 shares during the last quarter. Finally, Jafra Capital Management LP bought a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at about $7,661,000. 64.52% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Further Reading: Diversification Important in Investing

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.